Inflammatory Bowel Disease Treatment Market Report 2026

The inflammatory bowel disease treatment market size has grown strongly in recent years. It will grow from $27.19 billion in 2025 to $29.8 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rising prevalence of ulcerative colitis and crohn’s disease, growing awareness of ibd treatment options, expansion of hospital and retail pharmacy networks, availability of generic aminosalicylates, early adoption of biologics in developed regions.

The inflammatory bowel disease treatment market size is expected to see strong growth in the next few years. It will grow to $43.36 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing investment in precision medicine, development of novel anti-inflammatory therapies, integration of digital health platforms for patient monitoring, growth in biologics and biosimilars adoption, expansion of ibd treatment access in emerging markets. Major trends in the forecast period include personalized ibd therapy development, increasing use of biologics in treatment, minimally invasive drug delivery systems, rising focus on patient adherence programs, growth of specialty pharmacies for ibd.

The increasing prevalence of Crohn’s disease and ulcerative colitis is substantially contributing to the growth of the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are forms of inflammatory bowel disease (IBD) that lead to inflammation and ulcer formation within the digestive tract. The growing number of cases of these conditions is expected to raise demand for inflammatory bowel disease therapies, as these treatments are widely used to reduce intestinal inflammation and to manage and prevent related medical complications. For example, in November 2024, the Crohn’s & Colitis Foundation, a US-based non-profit organization, reported that approximately 100,429 children and adolescents under the age of 20 in the United States are living with IBD, including both Crohn’s disease and ulcerative colitis. Within this pediatric group, Crohn’s disease is more prevalent, with 71 cases per 100,000 individuals, compared to 44 cases per 100,000 for ulcerative colitis. Therefore, the rising prevalence of Crohn’s disease and ulcerative colitis is expected to drive growth in the inflammatory bowel disease treatment market.

Major companies operating in the inflammatory bowel disease treatment market are focusing on the development of innovative therapies, including treatments for moderate to severe active ulcerative colitis, to expand their customer base, increase sales, and drive revenue growth. Treatments for moderate to severe active ulcerative colitis generally involve pharmacological therapies and, in some cases, surgical interventions. For example, in October 2023, Eli Lilly and Company, a US-based pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) had approved Omvoh (mirikizumab-mrkz), which is available in both infusion (300 mg/15 mL) and injection (100 mg/mL) formulations. Omvoh is the first and only interleukin-23p19 (IL-23p19) antagonist approved for the treatment of adults with moderately to severely active ulcerative colitis. The therapy is specifically designed to target the p19 subunit of IL-23, thereby blocking the IL-23 pathway that plays a key role in driving inflammation associated with ulcerative colitis. The Omvoh treatment regimen starts with three 300-mg intravenous infusions administered once every four weeks, followed by a maintenance phase consisting of two 100-mg subcutaneous self-injections every four weeks.

In November 2023, Teva Pharmaceuticals, a US-based provider of inflammatory bowel disease treatments, entered into a collaboration with Sanofi to advance the development of innovative therapies. Through this partnership, Teva plans to speed up the development of its investigational treatment, TEV-574, for inflammatory bowel disease by utilizing Sanofi’s global clinical development and commercial capabilities. The collaboration is anticipated to facilitate the advancement of TEV-574 through clinical trials and enhance its potential reach in international markets. Sanofi is a France-based pharmaceutical company.

Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic - Gastroenterology West P.C.

North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inflammatory bowel disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the inflammatory bowel disease treatment market by increasing the cost of imported pharmaceutical ingredients and biologics, particularly impacting aminosalicylates, corticosteroids, and TNF inhibitors. Regions such as North America and Europe, which rely heavily on imports, face higher production and treatment costs. Hospital and retail pharmacy segments are most affected due to supply chain disruptions, whereas domestic manufacturers may benefit from increased local demand and incentives for local production, providing a modest positive impact on the market.

The inflammatory bowel disease treatment market research report is one of a series of new reports that provides inflammatory bowel disease treatment market statistics, including inflammatory bowel disease treatment industry global market size, regional shares, competitors with a inflammatory bowel disease treatment market share, detailed inflammatory bowel disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the inflammatory bowel disease treatment industry. This inflammatory bowel disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inflammatory bowel disease treatment involves the use of anti-inflammatory medications that are commonly prescribed for managing mild to moderate ulcerative colitis. Aminosalicylates, including mesalamine (Delzicol, Rowasa, and other brands), balsalazide (Colazal), and olsalazine (Dipentum), are key anti-inflammatory agents used in treatment.

The main drug classes used for inflammatory bowel disease treatment include aminosalicylates, corticosteroids, tumor necrosis factor (TNF) inhibitors, interleukin (IL) inhibitors, anti-integrin agents, Janus kinase (JAK) inhibitors, and others. Aminosalicylates are a group of medications utilized to treat and prevent flare-ups of ulcerative colitis and Crohn’s disease. Their mechanism of action involves inhibiting the production of cyclooxygenase and prostaglandins, thromboxane synthetase, platelet-activating factor synthetase, and interleukin-1 by macrophages. Inflammatory bowel disease treatments are administered orally or via injection and are used to manage both Crohn’s disease and ulcerative colitis. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The inflammatory bowel disease treatment market includes revenues earned by entities by reducing the inflammation that triggers the signs and symptoms. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.